YOLFTbeta
Shanghai Yizhong Pharmaceutical Co Ltd

Shanghai Yizhong Pharmaceutical Co Ltd

688091 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

35.57CNY-1.41 (-3.81%)

Price History

Full chart

Market Stats

Previous Close36.98
Open37.08
Day Range35.50 – 37.38
52-Week Range35.28 – 66.20
Volume1.89M
Market Cap8.14B
P/E (TTM)115.88
Forward P/E0.00
EPS0.34
Dividend Yield0.00%
Beta-0.44
50-Day Avg39.60
200-Day Avg48.33

About

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecological tumors. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jingsong Zhou
  • Employees457
  • HeadquartersNo.79 Renqi Road, Shanghai, China, 201401, China
  • Websitehttps://www.yizhongpharma.com

Leadership

  • Mr. Jingsong ZhouChairman & GM · b. 1968
  • Mr. Duan LiDeputy GM & Director · b. 1940
  • Ms. Jing SunDeputy GM & Director · b. 1977
  • Mr. Zhou FangBoard Secretary · b. 1988
  • Mr. Wenming ZhangDeputy General Manager · b. 1984
  • Tian RuanAccounting Supervisor

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--004.08M235.96M360.25M173.53M317.08M
Growth (%)-----+5686.75%+52.68%-51.83%+82.72%
Cost of Revenue-5.52M5.98M7.13M295.81K16.97M23.62M13.34M53.37M
Gross Profit--5.52M-5.98M-7.13M3.78M218.99M336.63M160.20M317.08M
Gross Margin----92.75%92.81%93.44%92.31%100.00%
Operating Expense-7.07M309.21M14.71M13.06M67.40M141.18M150.66M255.00M
Operating Income-10.06M-12.59M-315.19M-21.84M-9.28M151.59M195.45M9.54M62.08M
Operating Margin-----227.62%64.24%54.25%5.50%19.58%
EBITDA-5.72M-8.04M-310.21M-15.67M-2.10M155.99M195.10M16.78M72.12M
EBITDA Margin-----51.47%66.11%54.16%9.67%22.75%
Net Income-10.07M-12.59M-315.22M-21.85M-4.00M142.85M161.55M6.98M64.13M
Net Income Margin-----98.03%60.54%44.84%4.02%20.23%
R&D14.89M13.51M178.67M17.89M13.24M7.93M22.45M37.20M86.37M
R&D as % of Total Revenue----324.70%3.36%6.23%21.44%27.24%
Interest Expense-5.30K6.70K12.24K588.86K3.11K321.97K795.67K67.15K
Interest Expense % of Total Revenue----14.44%0.00%0.09%0.46%0.02%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets213.74M229.33M277.62M258.81M1.20B1.35B1.57B1.45B1.53B
Total Liabilities16.17M17.15M12.26M15.30M25.02M35.42M108.52M42.97M96.75M
Total Equity197.57M212.18M265.35M243.51M1.18B1.32B1.46B1.41B1.43B
Cash2.71M3.17M154.03K191.48K110.43M710.38M914.76M644.41M43.89M
Total Debt---3.25M16.75M-44.03M--
Net Debt-2.71M-3.17M-154.03K3.06M-93.68M-710.38M-870.74M-644.41M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.51M-10.68M-23.91M-20.21M-48.78M110.78M86.55M39.44M-19.38M
Investing Cash Flow14.06M-16.06M-50.80M17.00M-785.63M502.27M116.49M-192.65M-
Financing Cash Flow-27.20M71.70M3.25M944.65M-17.24M591.70K-112.27M-
Capital Expenditure1.13M3.46M47.58M5.00M3.14M35.88M8.78M80.04M130.09M
Free Cash Flow-12.64M-14.15M-71.48M-25.22M-51.93M74.90M77.77M-40.60M-149.47M
Dividends Paid----588.86K491.43K43.41M49.79M73.75K
FCF to OCF109.81%132.43%298.99%124.76%106.44%67.61%89.85%-102.95%771.16%
Dividend Paid to FCF-----1.13%0.66%55.81%-122.65%-0.05%

Earnings

Report DateSep 30, 2021Mar 31, 2022Apr 17, 2022Aug 18, 2022Oct 30, 2022Feb 28, 2023Apr 25, 2023
EPS Estimate-------
EPS Actual-0.050.110.210.210.300.270.35
Surprise-------
Timing-Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap8.14B
Enterprise Value8.03B
Trailing P/E115.88
Forward P/E0.00
Price / Sales25.32
Price / Book5.66
EPS0.34
Book Value6.74
Revenue (TTM)321.61M
Gross Profit (TTM)269.92M
EBITDA53.94M
Profit Margin21.41%
Operating Margin20.09%
Return on Equity4.69%
Return on Assets1.65%
Shares Outstanding206.70M
Shares Float104.42M
Beta-0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.31May 17, 2024
20231×
0.23Apr 20, 2023

Stock Splits

  • May 17, 20241.3:1
  • Apr 20, 20231.1:1
  • Oct 20, 20221.36:1